Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
TUCSON, Ariz., May 01, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 13619211), or from the webcast on the “Investors” section of the Company’s website at: www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: (415) 513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: (520) 547-2827 x130 Email: [email protected]
